Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.5% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report)’s stock price fell 5.5% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $9.37 and last traded at $9.42. 2,122,148 shares changed hands during trading, a decline of 70% from the average session volume of 7,091,171 shares. The stock had previously closed at $9.97.

Specifically, COO Tina Marriott Larson sold 8,000 shares of the firm’s stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $10.35, for a total transaction of $82,800.00. Following the sale, the chief operating officer now owns 414,548 shares in the company, valued at $4,290,571.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $10.35, for a total value of $82,800.00. Following the transaction, the chief operating officer now owns 414,548 shares in the company, valued at $4,290,571.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Shafique Virani sold 18,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $10.93, for a total value of $196,740.00. Following the completion of the transaction, the insider now owns 136,748 shares in the company, valued at approximately $1,494,655.64. The disclosure for this sale can be found here. Insiders have sold 362,254 shares of company stock worth $3,968,039 over the last 90 days. Corporate insiders own 19.96% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on RXRX. KeyCorp raised their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Finally, Needham & Company LLC lifted their price objective on Recursion Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $12.75.

Read Our Latest Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Trading Up 1.5 %

The company has a 50-day simple moving average of $11.11 and a two-hundred day simple moving average of $9.07.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The firm had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. On average, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock valued at $154,459,000 after buying an additional 158,376 shares during the period. Mubadala Investment Co PJSC bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $128,041,000. Goldman Sachs Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 79.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,191,805 shares of the company’s stock valued at $11,751,000 after buying an additional 527,032 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Recursion Pharmaceuticals by 6.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 56,564 shares of the company’s stock valued at $558,000 after buying an additional 3,589 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $107,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Stories

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.